<DOC>
	<DOC>NCT01460199</DOC>
	<brief_summary>This study is being conducted to evaluate the safety and tolerability of treatment with CTP-499 in non-dialysis patients associated with moderate chronic kidney disease.</brief_summary>
	<brief_title>Safety &amp; Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease</brief_title>
	<detailed_description>This study will evaluate the safety and tolerability of treatment with CTP-499 starting with 600 milligrams (mg) once a day (QD) for 2 weeks followed by 600 mg twice a day (BID) for 2 weeks in non-dialysis patients associated with moderate chronic kidney disease defined as an estimated Glomerular Filtration Rate or eGFR that is 30-59 mL/min/1.73m2</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Patient has a diagnosis of chronic kidney disease If taking antihypertensive and antidiabetes medications, regimen must be stable for a minimum of 4 weeks Patient has systolic blood pressure less than or equal to 160 mm Hg and diastolic blood pressure less than or equal to 95 mm Hg Patient has concurrent condition such as uncontrolled inflammatory disease, acute infection or clinically unstable autoimmune, endocrine, neurological, psychiatric, retinal, cardiovascular, bronchopulmonary, hepatic, gastrointestinal or musculoskeletal disorder Patient has acute, active and/or current unstable renal impairment disease Patient has been hospitalized for acute renal failure in the past year Patient has active malignancy or a history of neoplastic disease Patient has QTc interval &gt; 450 milliseconds Patient is currently on cytotoxic or other immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>